Analysis: Japan Drug System Encourages Moves Abroad
This article was originally published in PharmAsia News
Oncolys BioPharma's experience with getting its Telomelysin carcinostatic drug through the U.S. FDA process highlights the legal and bureaucratic red tape of Japan's process, according to an analysis. The firm's president noted the U.S. FDA even advises a drug maker on which tests will not be needed while Japan has in place hurdles too high for small ventures to scale. There have been recent signs of change in Japan, but its domestic market is likely to continue to lag as Japanese drug makers move testing and sales elsewhere. (Click here for more - a subscription may be necessary
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.